CO-ALEPH-OBJECTS
12.6.2019 07:02:29 CEST | Business Wire | Press release
Aleph Objects, Inc., manufacturer of LulzBot 3D Printers, announced their collaboration with FluidForm Inc., an innovator in 3D bioprinting. FluidForm’s FRESH printing technique, developed in Carnegie Mellon University’s Regenerative Biomaterials and Therapeutics Group, enables 3D printing of bioinks and other soft materials. Together, Aleph Objects and FluidForm will combine their expertise to offer new bioprinting solutions, with the initial offering coming this summer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611006066/en/
3D bioprinting is already being used in labs to create tissue scaffolds and other complex biological structures. “We’re still at the very beginning of being able to build real functional tissues with 3D bioprinting,” said FluidForm CTO Adam Feinberg. “Collaborations like the one we are building with LulzBot will help make this a reality faster.”
3D biofabrication technology is revolutionizing applications across a wide spectrum of industries, including pharmaceuticals, regenerative medicine, drug screening, food and other animal products, cell-based biosensors, and testing of cosmetics and other health care goods. Within the next decade, major pharmaceutical companies will be able to replace some animal testing and non-physiological 2D cell culture systems with clinically-relevant 3D bioprinted human tissues.
FluidForm’s novel platform of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D printing enables fabrication of soft, biological scaffolds for applications in tissue engineering and regenerative medicine.
“Combining proven expertise in professional 3D printers and hardware with 3D biofabrication technology is going to be an absolute game-changer,” said Aleph Objects CEO and President Grant Flaharty. “The market for 3D bioprinters and 3D bioprinted tissues is estimated to grow to $1.9 billion by 2028.”
Subscribe and be the first to learn about LulzBot’s bioprinting advancements and new products! https://www.lulzbot.com/Bio
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers. LulzBot is a trusted brand in Automotive, Consumer Products, Aerospace/Defense, Medical, and Education industries around the globe. Aleph Object’s core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination to life. For more information, visit www.LulzBot.com .
Media Assets: https://own.alephobjects.com/s/XeJkaLJWHSzByib
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611006066/en/
Contact:
Press Contact: Eric Beardslee press@lulzbot.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 19:23:00 CEST | Press release
SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom